Ebp1 Expression in Prostate Cancer
Author Information
Author(s): Gannon Philippe O, Koumakpayi Ismaël Hervé, Le Page Cécile, Karakiewicz Pierre I, Mes-Masson Anne-Marie, Saad Fred
Primary Institution: Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM)
Hypothesis
Does Ebp1 expression correlate with prostate cancer progression and predict biochemical recurrence?
Conclusion
Ebp1 expression increases with prostate cancer progression, but it does not predict PSA relapse on its own.
Supporting Evidence
- Ebp1 expression significantly increased from normal to hormone-sensitive to hormone-refractory prostate cancer.
- Ebp1 did not predict PSA relapse on its own.
- High Ebp1 expression correlated with high nuclear expression of AR, Cyclin D1, and ErbB3.
Takeaway
This study looked at a protein called Ebp1 in prostate cancer and found that while it gets more common as cancer gets worse, it doesn't help predict if someone will have a relapse after surgery.
Methodology
Immunohistochemistry was used to evaluate Ebp1 expression in tissue micro-arrays of prostate tissues, followed by multivariate COX regression analysis.
Potential Biases
Potential bias in patient selection and tissue sampling.
Limitations
The study is limited by its retrospective design and the reliance on tissue micro-arrays.
Participant Demographics
The study included 138 patients with prostate cancer, with a median age of 62 years.
Statistical Information
P-Value
0.170 for normal adjacent expression, 0.689 for tumor expression
Confidence Interval
95% CI for Ebp1: 1.75(0.79–3.89) for normal adjacent, 1.15(0.58–2.26) for tumor
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website